Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
Conclusions: TLC demonstrated promising effects and tolerable safety in HER2+MBC, even in patients with BM, providing a theoretical basis for clinical practice.Clinical Trial Registration:ClinicalTrials.gov, Identifier: NCT04001634.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | HER2 | Herceptin | Neurology | Study | Toxicology | Xeloda